Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q2 2018 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. Look for any mention of deals, orders, contracts, projects, customers, sites, or programs getting bigger over time. Scan the transcript for relevant statements. Brian Jellison and others discuss various segments. Look for phrases like "larger", "bigger", "more seats", "net new customers", "larger clients", "larger projects", "multiple facilities", "double-digit growth", etc. But we need specifically a comparison against the company's own past for the same offering, indicating escalation of unit size. Check for any mention of average deal size increasing, customers starting at higher levels, etc. I see mentions of "large wins" in Deltek, "significant adds in net subscribers" for freight matching, "double-digit growth" in various places. But is there any explicit statement that the size of individual deals or contracts is escalating? For example, in ConstructConnect: "expand into what we want to do with it. It's a great network business. We want to have it broaden out to more software, so it can serve larger clients with larger projects" - that sounds like an ambition, not yet realized. Also "on track for where we expect it to be" - not a present-tense reality. In PowerPlan: "multiple growth opportunities" but not about size escalation. In toll and traffic: "we're getting double-digit growth" but that's overall growth, not necessarily unit size. In Medical: "good market adoption of Verathon's new BladderScan technology" - not about size. In Industrial: "meaningful share gains" - that's market share, not unit size. In Energy: "returned to growth" - not about size. No mention of "average order size" or "larger contracts" as a trend. The only mention of "larger" is in ConstructConnect where it's a future goal. Also "larger clients" is an ambition. Thus, no evidence of management conveying that the unit size of repeatable business is escalating. They talk about strong growth, more customers, but not that each new instance is bigger than the last. Therefore, answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.